| 规格: | 98% |
| 分子量: | 464.5 |
| 包装 | 价格(元) |
| 500ug | 电议 |
| 1mg | 电议 |
Background:
Clindamycin-d3is intended for use as an internal standard for the quantification of clindamycin by GC- or LC-MS. Clindamycin is a lincosamide antibiotic.1,2It is active against Gram-positive bacteria, including various strains ofS. pneumoniae,S. viridans,S. aureus, andS. epidermidis(MICs = 0.002-0.1, 0.005-0.2, 0.04-1.6, and 0.1-0.2 µg/ml, respectively).1Clindamycin is also active against chloroquine-resistant and -sensitive strains ofP. falciparum(IC50s = 3.12 and 8.81 nM, respectively).2It inhibits bacterial protein synthesis by interacting with the 50S ribosome.1Clindamycin increases survival in a mouse model of a secondaryS. pneumoniaeinfection when administered at a dose of 15 mg/kg twice daily for seven days.3Formulations containing clindamycin have been used in the treatment of bacterial infections.
1.SpÍ?ek, J., and ?ezanka, T.Lincomycin, clindamycin and their applicationsAppl. Microbiol. Biotechnol.64(4)455-464(2004) 2.Dahl, E.L., and Rosenthal, P.J.Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplastAntimicrob. Agents Chemother.51(10)3485-3490(2007) 3.KarlstrÖm, Å., Boyd, K.L., English, B.K., et al.Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenzaJ. Infect. Dis.199(3)311-319(2009)
m.cnreagent.com